Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Income - Net (2023 - 2025)

Guided Therapeutics' Interest Income - Net history spans 3 years, with the latest figure at -$157000.0 for Q2 2025.

  • For Q2 2025, Interest Income - Net fell 109.33% year-over-year to -$157000.0; the TTM value through Jun 2025 reached -$546000.0, down 100.0%, while the annual FY2024 figure was -$378000.0, 38.97% down from the prior year.
  • Interest Income - Net for Q2 2025 was -$157000.0 at Guided Therapeutics, down from -$147000.0 in the prior quarter.
  • Across five years, Interest Income - Net topped out at -$61000.0 in Q1 2024 and bottomed at -$157000.0 in Q2 2025.
  • The 3-year median for Interest Income - Net is -$73000.0 (2023), against an average of -$95400.0.
  • The largest annual shift saw Interest Income - Net increased 7.58% in 2024 before it plummeted 140.98% in 2025.
  • A 3-year view of Interest Income - Net shows it stood at -$66000.0 in 2023, then crashed by 103.03% to -$134000.0 in 2024, then fell by 17.16% to -$157000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Interest Income - Net are -$157000.0 (Q2 2025), -$147000.0 (Q1 2025), and -$134000.0 (Q4 2024).